Tercica is committed to improving endocrine and metabolic health with products that are safe and effective for patients to use. One of the most important ways we demonstrate that commitment is through clinical research programs. As study data is collected, we share our findings with the scientific and clinical communities at medical conferences, and with investors through webcasts.

At present, Tercica is conducting — or preparing to conduct — nine clinical trials involving Increlex^® (mecasermin [rDNA origin] injection) and Somatuline^® Depot (lanreotide) Injection. These include five Increlex^® pediatric studies, two Increlex/rhGH combination pediatric and adult studies, and two Somatuline^® Depot studies. We also track the ongoing health of patients who are using our products through patient registries.

For a detailed description of Tercica's ongoing clinical studies and patient registries, download our Clinical Studies Brochure. If you are a patient or healthcare professional and would like to inquire about participation in our clinical studies, you may e-mail a Tercica medical science liaison or call 1-866-837-2422.